Page 6 - Swiss Pharma Company News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Swiss pharma company. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Swiss Pharma Company Today - Breaking & Trending Today

ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Lugano, Switzerland, and Osaka, Japan, January 22, 2021 - Helsinn Group (Lugano, Switzerland; CEO: Riccardo Braglia, “Helsinn”) and Ono Pharmaceu. ....

South Korea , Kiyoaki Idemitsu , Riccardo Braglia , Gyo Sagara , Helsinn Investment Fund , Helsinn Group Vice , Swiss Pharma Company , China Helsinn Pharmaceuticals , Ono Pharmaceutical Co Ltd , Helsinn Group , Helsinn Group Lugano , Ireland Helsinn Birex Pharmaceuticals , Clinical Development , Marketing Approval , Ghrelin Receptor Agonist , Cancer Cachexia , Representative Director , Helsinn Group Vice Chairman , Corporate Executive Officer , Executive Director , Management Plan , Helsinn Healthcare , Helsinn Therapeutics , Helsinn Pharmaceuticals China , Helsinn Advanced Synthesis , Helsinn Birex Pharmaceuticals ,

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with .
Helsinn Healthcare S.A.January 12, 2021 GMT
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities. ....

Paola Bonvicini , Riccardo Braglia , Helsinn Investment Fund , Helsinn Group Vice , Taiho Pharmaceutical Co Ltd , Swiss Pharma Company , China Helsinn Pharmaceuticals , Group Head Of Communication , Helsinn Group Media Contact , Helsinn Group , Ireland Helsinn Birex Pharmaceuticals , Otsuka Holdings Co Ltd , Helsinn Announces First Patient Dosed , Advanced Solid Tumors , Helsinn Group Vice Chairman , Non Small Cell Lung Cancer , Helsinn Healthcare , Helsinn Therapeutics , Helsinn Pharmaceuticals China , Helsinn Advanced Synthesis , Helsinn Birex Pharmaceuticals , Taiho Pharmaceutical , Group Media Contact , Products And Services , Western Europe , Product Testing ,

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
January 12, 2021 03:30 ET
| Source:
Helsinn Healthcare S.A.
Helsinn Healthcare S.A.
Lugano/Pazzallo, SWITZERLAND
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
TAS0953/HM06 is an investigational oral treatment which inhibits several RET abnormalities identified as oncogenic driver alterations in NSCLC, papillary and medullary thyroid cancers, and several other tumor types. This ....

Paola Bonvicini , Johns Hopkins , Riccardo Braglia , Helsinn Investment Fund , Helsinn Group Vice , Taiho Pharmaceutical Co Ltd , Swiss Pharma Company , China Helsinn Pharmaceuticals , Group Head Of Communication , Helsinn Group Media Contact , Helsinn Group , Otsuka Holdings Co Ltd , Ireland Helsinn Birex Pharmaceuticals , Announces First Patient Dosed , Advanced Solid Tumors , Helsinn Group Vice Chairman , Non Small Cell Lung Cancer , Helsinn Healthcare , Helsinn Therapeutics , Helsinn Pharmaceuticals China , Helsinn Advanced Synthesis , Helsinn Birex Pharmaceuticals , Taiho Pharmaceutical , Group Media Contact , Cancer Biol Ther , Cell Rep ,

Helsinn Healthcare S.A.: Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

(1)
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
Lugano, Switzerland, January 12, 2021 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities.
TAS0953/HM06 is an investigational oral treatment which inhibits several RET abnormalities identified as oncogenic driver alterations in NSCLC, papillary and medullary thyroid cancers, and several other tumor types. This innovative drug candidate offers several differentiating features as compared to other RET inhibitors. ....

Kostenloser Wertpapierhandel , Paola Bonvicini , Johns Hopkins , Riccardo Braglia , Helsinn Investment Fund , Helsinn Group Vice , Taiho Pharmaceutical Co Ltd , Swiss Pharma Company , China Helsinn Pharmaceuticals , Group Head Of Communication , Helsinn Group Media Contact , Helsinn Group , Otsuka Holdings Co Ltd , Ireland Helsinn Birex Pharmaceuticals , Helsinn Announces First Patient Dosed , Advanced Solid Tumors , Helsinn Group Vice Chairman , Non Small Cell Lung Cancer , Helsinn Healthcare , Helsinn Therapeutics , Helsinn Pharmaceuticals China , Helsinn Advanced Synthesis , Helsinn Birex Pharmaceuticals , Taiho Pharmaceutical , Group Media Contact , Cancer Biol Ther ,